Journal of Neuro-Oncology

, Volume 65, Issue 1, pp 37–48 | Cite as

Interleukin-13 Receptor-Directed Cytotoxin for Malignant Glioma Therapy: From Bench to Bedside

  • Syed R. Husain
  • Raj K. Puri


Central nervous system malignant neoplasias, in particular, glioblastoma multiforme (GBM) have defied all current therapeutic modalities. New therapies involving tumor targeting approach are being explored. This approach relies on the identification of unique or over-expressed cell surface receptors or antigens on tumor cells. In that regard, we have identified receptor for an immune regulatory cytokine, interleukin-13 (IL-13), which is over-expressed on human malignant glioma cell lines and primary tumor cell cultures. To target IL-13 receptors (IL-13R) for cancer therapy, we have developed a recombinant fusion protein composed of IL-13 and a mutated form of Pseudomonas exotoxin (IL13-PE38QQR or IL-13 cytotoxin). The IL-13 cytotoxin was found to be highly selective and potent in killing human GBM cells in vitro while normal cells including immune cells, endothelial cells and normal brain cells were generally spared the cytotoxic effect of IL-13 cytotoxin. This is because these cells either expressed none or expressed low levels of IL-13R.

Consistent with in vitro cytotoxic activity, IL-13 cytotoxin mediated remarkable anti-tumor activity to human glioma in animal xenograft models. The direct injection of IL-13 cytotoxin into subcutaneous human GBM tumors grown in nude mice produced complete and durable regression of established tumors. Intravenous and intraperitoneal administration of IL-13 cytotoxin also reduced tumor burden significantly with fewer complete responders. All animals tolerated therapy well with minimal toxicity to vital organs. Pre-clinical safety and toxicity studies were performed in mice, rats and monkeys. Systemic administration of IL-13 cytotoxin appeared to be well tolerated at high doses (up to 50ug/kg). Intrabrain parenchyma administration of IL-13 cytotoxin at doses up to 100ug/ml was very well tolerated without any evidence of gross or microscopic necrosis, whereas at 500ug/ml dose, localized necrosis was observed in normal rat brain. Based on these encouraging pre-clinical studies, three Phase I/II clinical trials in adults with malignant glioma have been initiated. The first clinical trial involves convection-enhanced delivery (CED) of IL-13 cytotoxin into recurrent malignant glioma. This route of IL-13 cytotoxin administration appears to be fairly well tolerated with no neurotoxicity. The second clinical trial involves infusion of IL-13 cytotoxin by CED following tumor resection. The initial stage of the second study assessed histologic effect of drug administered prior to resection. In third one, IL-13 cytotoxin is infused by CED followed by tumor resection. All three clinical trials are currently ongoing.

anti-tumor activity brain tumor fusion protein glioblastoma IL-13 cytotoxin clinical trial IL-13-PE38 IL-13 receptor nude mice receptor targeting tumor regression 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg LX, Edwards BK (eds): SEERS Cancer Statistics Review, 1973–1997, National cancer Institute. NIH Pub. No. 00-2789. Bethesda, MD, 2000Google Scholar
  2. 2.
    National Center for Health Statistics for the United States: Public Health Service, Washington DC, 1997Google Scholar
  3. 3.
    Galanis E, Buckner JC, Dinapoli, RP et al.: Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg 89: 425–430, 1998Google Scholar
  4. 4.
    Brandes A, Ermani M, Basso U, Amista P, Berti F, Scienza R, Rotilio A, Pinna G, Gardiman M, Monfardini S: Ann Oncol 12: 1, 2001Google Scholar
  5. 5.
    Brandes A, Vastola F, Monfardini S: Am J Clin Oncol 22: 387, 2001Google Scholar
  6. 6.
    Grana C, Chinol M, Robertson C et al.: Br J cancer 86: 207–212, 2002Google Scholar
  7. 7.
    Valery CA, Seilhean D, Boyer O, Marro B, Hauw JJ, Kemeny JL, Marsault C, Philippon J, Klatzmann D: Long term survival after gene therapy for a recurrent glioblastoma. Neurology 58: 1109–1112, 2002Google Scholar
  8. 8.
    Lam PYD, Breakfield XO: Potential of gene therapy for brain tumors. Human Mol Genet 10: 777–787, 2001Google Scholar
  9. 9.
    Deen DF, Chiarodo A, Frimm EA, Fike JR, Israel MA, Kun LF, Levin FA, Marton LJ, Packer RJ, Pegg AE, Rosenblum ML, Suit HD, Walker MD, Wikstrand CJ, Wilson CB, Wong AJ, Yung WKA: Brain tumor working group report on the 9th international conference on brain tumor research and therapy. J Neuro-Oncol 16: 243–272, 1993Google Scholar
  10. 10.
    Hao CH, Parney IF, Roa WH et al.: Cytokine and cytokine receptormRNAexpression in human glioblastoma: evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta Neuropathol 103: 171–178, 2002Google Scholar
  11. 11.
    Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by transforming growth factor antisense gene therapy. Proc Natl Acad Sci 93: 2909–2914, 1996Google Scholar
  12. 12.
    Yamada SM, Yamada SH, Takahashi H, Teramoto A, Matsumoto K: Fibroblast growth factor receptor (FGFR)4 correlated with the malignancy of human astrocytoma. Neurological Res 24: 244–248, 2002Google Scholar
  13. 13.
    Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K: Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with monoclonal antibody against vascular endothelial growth factor receptor. Cancer Res 61: 6624–6628, 2001Google Scholar
  14. 14.
    Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, Baserga R, Iliakis G, Aiken RD: Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I in malignant astrocytomas. J Clin Oncol 19(8): 2189–2200, 2001Google Scholar
  15. 15.
    Crombet T, Torres O, Rodriguez V et al.: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma 20: 131–136, 2001Google Scholar
  16. 16.
    Kreitman RJ: Immunotoxin in cancer therapy. Curr Opin Immunol 11: 570–578, 1999Google Scholar
  17. 17.
    Brandes AA, Basso U, Pasetto LM, Ermani B: New strategy developments in brain tumor therapy. Curr Pharm Design 7: 1553–1580, 2001Google Scholar
  18. 18.
    Basso U, Ermani B, Vastola F, Brandes AA: Non-cytotoxic therapies for malignant glioma. J Neuro-Oncol 58: 57–69, 2002Google Scholar
  19. 19.
    Amlot PL, Stone MJ, Cunnigham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramilo O, Thorpe PE, UhrJW, Vitetta ES:APhase I study of 47 an anti-CD22-deglycosylated RicinAchain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82: 2624–2633, 1993Google Scholar
  20. 20.
    Phillips PC, Levow C, Caterall M, Colvin OM, Pastan I, Brem H: Transforming growth factor–Pseudomonas exotoxin fusion protein (TGF–Pe38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res 54: 1008–1015, 1994Google Scholar
  21. 21.
    Vallera DA, Li C, Jin N, Panoskaltsis-Mortari A, Hall WA: Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Cancer Inst 94: 597–606, 2002Google Scholar
  22. 22.
    Li C, Hall WA, Jin N, Panoskaltsis-Mortari A, Vallera DA: Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng 15: 419–427, 2002Google Scholar
  23. 23.
    Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Med 3: 1362–1368, 1997Google Scholar
  24. 24.
    Oldfield EH, Youle RJ: Immunotoxin for brain tumor therapy. Curr Opin Microbiol 234: 97–114, 1998Google Scholar
  25. 25.
    Brown KD, Zurawski SM, Mosmann TR, Zurawski G: A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol 142: 679, 1989Google Scholar
  26. 26.
    Minty A, Chalon P, Derocq J-M, Dumont X, Guillemot J-C, Kaghad M, Labit C, Leplatois P, Miloux B, Minty C, Casellas P, Loison G, Lupker J, Shire D, Ferrara P, Caput D: Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362: 248, 1993Google Scholar
  27. 27.
    Zurawski G, DeVries JE: Interleukin-13 is an interleukin-4-like cytokine that acts on monocytes and B cells but not on T cells. Immunol Today 15: 19–26, 1994Google Scholar
  28. 28.
    Defrance T, Carayon P, Billian G, Guillemot J-C, Minty A, Caput D, Ferrara P: Interleukin-13 is a B cell stimulatory factor. J Exp Med 179, 135–143, 1994Google Scholar
  29. 29.
    Herber J-M, savi P, Laplace MC, Lale A, Dol F, Dumas A, Labit C, Minty A: IL-4 and IL-13 exhibit comparable abilities to reduce pyrogen-induced expression of procoagulant activity in endothelial cells and monocytes. FEBS Lett 328: 268–270, 1993Google Scholar
  30. 30.
    Obiri NI, Debinski W, Leonard WJ, Puri RK: Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common ? chain shared by receptors for interleukin 2, 4, 7, 9, and 15. J Biol Chem 270: 8797, 1995Google Scholar
  31. 31.
    Idzerda RL, March CJ, Mosley B, Lyman SD, Bos TV, Gimpel SD, Din WS, Grabstein KH, Widmer MB, Park LS, Cosman D, Beckman MP: Human interleukin 4 receptor confers biological responses and defines a novel receptor superfamily. J Exp Med 171: 861–873, 1990Google Scholar
  32. 32.
    Puri RK, Leland P, Kreitman RJ, Pastan I: Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL-4-Pseudomonas exotoxin chimeric protein. Int J Cancer 58: 574–581, 1994Google Scholar
  33. 33.
    Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK: Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res 1: 1253–1258, 1995Google Scholar
  34. 34.
    Husain SR, Obiri NI, Gill P, Zheng T, Pastan I, Debinski W, Puri RK: Receptors for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res 3: 151–156, 1997Google Scholar
  35. 35.
    Obiri NI, Murata T, Debinski W, Puri RK: Modulation of interleukin (IL)-13 binding and signaling by the ? c chain of the IL-2 receptor. J Biol Chem 272: 20251–20258, 1997Google Scholar
  36. 36.
    Murata T, Husain SR, Mohri H, Puri RK: Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol 10: 1103–1110, 1998Google Scholar
  37. 37.
    Obiri NI, Leland P, Murata T, Debinski W, Puri RK: The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor complex. J Immunol 158: 756–764, 1997Google Scholar
  38. 38.
    Miloux B, Laurent P, Bonnin O, Luker J, Caput D, Vita N, Ferrara P: Cloning of the human IL-13Ralpha1 chain and reconstitution with the IL-4Ralpha of functional IL-4/IL-13 receptor complex. FEBS Lett 401: 163–166, 1997Google Scholar
  39. 39.
    Hilton DJ, Zhang, JG, Metcalf D, Alexander WS, Nicola NA, Wilson TA: Cloning and characterization of binding subunits of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc Natl Acad Sci 93: 497–501, 1996Google Scholar
  40. 40.
    Aman MJ, Tayebi N, Obiri NI, Puri RK, Modi WS, Leonard W: cDNA cloning and characterization of the human interleukin 13 receptor ? chain. J Biol Chem 271: 29265–29670, 1996Google Scholar
  41. 41.
    Murata T, Obiri NI, Puri RK: Structure and signal transduction through interleukin-4 and interleukin-13 receptors, Int J Mol Med 1: 551–557, 1998Google Scholar
  42. 42.
    Kawakami M, Leland P, Kawakami K, Puri RK: Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol Res 12: 459–467, 2001Google Scholar
  43. 43.
    Caput D, Laurent P, Kaghad M, Lelias JM, Lefort S, Vita N, Ferrara P: Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to IL-5 receptor ?hain. J Biol Chem 271: 16921–16926, 1996Google Scholar
  44. 44.
    Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, O'Hara Jr RM, Beier DR, Turner KJ, Wood CR, Collins M: The murine IL-13 receptor ą2: molecular cloning, characterization, and comparison with murine Il-13 receptor ą1. J Immunol 161: 2317–2324, 1998Google Scholar
  45. 45.
    Murata T, Obiri NI, Debinski W, Puri RK: Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Comm 238: 90–94, 1997Google Scholar
  46. 46.
    Joshi BH, Husain SR, Puri RK: Preclinical studies with IL-13PE38QQR for therapy of malignant glioma. Drug News Perspect 13: 599–605, 2000Google Scholar
  47. 47.
    Husain, SR, Puri RK: Interleukin-13 fusion cytotoxin as a potent targeted drug for AIDS-Kaposi's sarcoma xenograft. Blood 95: 3506–3513, 2000Google Scholar
  48. 48.
    Kawakami K, Kawakami M, Snoy P, Husain SR, Puri RK: In vivo overexpression of IL-13 receptor ą2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med 196: 1743–1754, 2001Google Scholar
  49. 49.
    Kawakami K, Husain SR, Bright RK, Puri RK: Gene transfer of interleukin 13 receptor ?2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther 8: 861–868, 2001Google Scholar
  50. 50.
    Schnyder B, Lugi S, Fenf N, Etter H, Lutz RA, Ryffel B, Sugamura K, Wunderli-Allenspach H, Moser R: Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common ? chain. Blood 87: 4286–4295, 1996Google Scholar
  51. 51.
    Vita N, Lefort S, Laurent P, Caput D, Ferrara P: Characterization and comparison of the interleukin 13 receptor with the interleukin 4 receptor on several cell types. J Biol Chem 270: 3512–3517, 1995Google Scholar
  52. 52.
    Kawakami K, Taguchi J, Murata T, Puri RK: The interleukin-13 receptor ą2 chain: an essential component for binding and internalization but not interleukin-13-induced signal transduction through the STAT6 pathway. Blood 97: 2673–2679, 2001Google Scholar
  53. 53.
    Joshi BH, Plautz GE, Puri RK: Interleukin-13 receptor a chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 60: 1168–1172, 2000Google Scholar
  54. 54.
    Debinski W, Obiri NI, Pastan I, Puri RK: A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 270: 16775–16780, 1995Google Scholar
  55. 55.
    Pastan I, Chaudhary VK, FitzGerald D: Recombinant toxins as novel therapeutic agents. Annu Rev Biochem 61: 331–354, 1992Google Scholar
  56. 56.
    Joshi BH, Kawakami K, Leland P, Puri RK: Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity of to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res 8: 1948–1956, 2002Google Scholar
  57. 57.
    Husain SR, Joshi, BJ, Joshi, Puri RK: Interleukin-13 receptors as a unique target for anti-glioblastoma therapy. Int J Cancer 92: 168–175, 2001Google Scholar
  58. 58.
    Weingart J, Strauss LC, Grossman SA, Markett J, Tatter S, Fisher JD, Fleming CK, Puri RK: Phase I/II study: intratumoral infusion of IL13-PE38QQR cytotoxin for recurrent supratentorial malignant glioma. Neuro-oncology 4: 379, 2002Google Scholar
  59. 59.
    Weingart J, Grossman SA, Bohan E, Fisher JD, Strauss L, Puri RK: Phase I/II study of interstitial infusion of IL13-PE38QQR cytotoxin in recurrent malignant glioma. First Quadrennial meeting-World Federation of Neuro-Oncology. November 15–17, Washington, DC, 2001Google Scholar
  60. 60.
    Prados MD, Lang FF, Strauss L, Fleming C, Alalpe K, Kunwar S, Yung WKA, Chang S, Husain SR, Gutin P-H, Raizer J, Piepmeier JM, Berger M, McDermott M, Puri RK: Intratumoral and intracerebral microinfusion of IL13-PE38QQR cytotoxin: Phase I/II study of pre-and postresection infusions in recurrent resectable malignant glioma. Am Soc Clin Oncol 2002Google Scholar
  61. 61.
    Lang F, Kunwar S, Strauss L, Gutin P, Piepmeier J, McDermott M, Fleming C, Sherman J, Raizer J, Alalpe K, Yung WKA, Husain SR, Chang S, Berger M, Prados M, Puri RK: A clinical study of convection-enhanced delivery of IL13-PE38QQR cytotoxin pre-and post-resection of recurrent GBM. Am Soc Neuro-Oncol Chicago, April 2002Google Scholar
  62. 62.
    Prados MD, Lang FF, Sherman JW, Strauss LC, Fleming CK, Alalpe K, Kunwar S, Yung WKA, Chang SM, Husain SR, Gutin PH, Raizer J, Piepmeier JM, Berger M, McDermott M, Puri RK: Convectionenhanced delivery (CED) by positive pressure infusion for intra-tumoral and peri-tumoral administration of IL13-PE38QQR a recombinant tumor-targeted cytotoxin in recurrent malignant glioma. Neuro-Oncology 4: S78, 2002Google Scholar
  63. 63.
    Prados MD, Lang FF, Strauss LC, Fleming CK, Alalpe K, Kunwar S, Yung WKA, Husain SR, Chang SM, Gutin PH, Raizer J, Piepmeier JM, Berger M, Puri RK: Pre-and post-resection interstitial infusion of IL13-PE38QQR cytotoxin: Phase I study in recurrent resectable malignant glioma. World Federation of Neuro-Oncology First Quadrennial Meeting/Society for Neuro-Oncology Sixth Annual Meeting, Washington DC, Nov. 15-18, 2001Google Scholar
  64. 64.
    Kawakami K, Joshi BH, Puri RK: Sensitization of cancer cells to interleukin-13-Pseudomonas exotoxin-induced cell death by gene transfer of interleukin-13? chain. Hum Gene Ther 11: 1829–1835, 2000Google Scholar
  65. 65.
    Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK: Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6: 2157–2165, 2000Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Syed R. Husain
    • 1
  • Raj K. Puri
    • 1
  1. 1.Laboratory of Molecular Tumor Biology, Division of Cellular and Gene TherapiesCenter for Biologics Evaluation and Research, FDABethesdaUSA

Personalised recommendations